This is a non-randomized parallel pilot study conducting through the Chinese University of Hong Kong looking at the safety and efficacy of using fecal microbiota transplantation (FMT) for the treatment of ITP. FMT has been used previously in the treatment of other autoimmune disorders and has in some cases been shown to reduce symptoms of the disorder. FMT is an innovative investigational treatment that has demonstrated in randomized, controlled clinical trials to be effective in resolving infections caused by recurrent C. difficile that does not respond to antibiotics. FMT works by transferring fecal microbiota cells from a healthy donor into the colon of the receiving participant. This study is open to individuals with ITP of all ages.